Natrecor for Pulmonary Hypertension in Lung Transplants

Completed · Phase 4

Conditions studied: Pulmonary Hypertension

In brief

This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO use by matched historical controls.

Key facts

Study ID

NCT00205426

Run by

University of Wisconsin, Madison

People needed

7

Starts

2005-08-01

Expected to finish

2006-05-01

Last updated by the study team

2015-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Single or double lung transplant or heart/lung transplant recipient
• Planned use of Natrecor
• Pulmonary artery (PA) systolic pressures > 35

You may not qualify if…

• Previous lung transplant
• Use of Prolastin after pneumonectomy
• Mean arterial pressure of < 55
• Known allergy or sensitivity to nesiritide
• Females of childbearing potential with a positive pregnancy test or women who are breast feeding
• Use of nesiritide, for any reason, within 30 days prior to transplant

Where it is running

• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.